May cause injection site reactions Some patients may experience mild reactions such as redness, swelling, itching, etc
But its still worth bringing up to your healthcare provider
This dual action enhances its ability to manage blood sugar levels and offers additional metabolic benefits
Weight interventions improve PsA outcomes PsA treatment guidelines support obesity management in patients with active PsA and obesity GRAPPA recommends maintenance of a healthy weight to improve disease activity and minimize disease impact 8 ACR recommends weight loss for patients with overweight/obesity 15 EULAR recommends that comorbidities such as obesity, metabolic syndrome, cardiovascular disease or depression should be considered managing patients with PsA 16 The modalities of weight management include lifestyle modification (nutrition, physical activity, psychological and behavioral intervention), pharmacotherapy, and bariatric surgery 17-20 Diet-based weight reduction is associated with achievement of MDA in patients with PsA and overweight/obesity starting TNFi therapy 6 5% weight reduction is the major and independent predictor of achieving MDA 6 Odds of achieving MDA increase with higher percent of weight reduction 6 In the DIPSA trial, weight loss magnitude was significantly associated with improvement in clinical outcomes, including DAPSA, pain, fatigue, PsAID, and TJC
Free consultation is available
Rybelsus (oral semaglutide for type 2 diabetes) Rybelsus is the brand name for FDA-approved oral semaglutide tablets containing SNAC permeation enhancer
